Adding two anti-inflammatory drugs to standard immunotherapy for melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether adding anakinra and tocilizumab to the usual combination of nivolumab and ipilimumab can improve treatment for melanoma. It is for people aged 50 or older who are about to start this standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 50 years old or older.
- You must have melanoma and be planning to receive the standard treatment with nivolumab and ipilimumab.
- You should be in generally good health, able to care for yourself (ECOG score 0 or 1).
- Your blood counts and liver/kidney function must be within certain limits.
- You cannot have an active autoimmune disease or be taking strong immune-suppressing medicines.
- You must agree to use effective birth control during the study and for 90 days after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.
This trial tests if injecting two immunotherapy drugs (ipilimumab and nivolumab) just under the skin can help prevent high-risk stage II melanoma from spreading. It is for people who have recently had a thick melanoma removed and have not yet had a sentinel node biopsy.
This trial tests a combination of three drugs (interferon, an immunotherapy drug called toripalimab, and an anti-cancer drug called anlotinib) in people with advanced melanoma that cannot be removed with surgery. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a type of immune cell therapy called cytokine-induced killer cells for people with advanced melanoma that has not responded to other treatments. It aims to see if these cells can help shrink or slow down the cancer.
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.